24 jan: Opjustering af resultatforventning for regnskabsåret 2016/17
25 jan: Indre værdi af SmallCap Danmark A/S er opgjort til 84,6 kr. pr. ..
25-01-2017 08:00:00

Lundbeck and IBM Watson Health form collaboration on technology for developing innovative medicine

Relateret indhold
26 apr - 
Onsdagens aktier: Rekordernes tid fortsatte med Novozym..
26 apr - 
Onsdagens aktier: Rekordernes tid fortsatte med Novozym..
24 apr - 
Mandagens aktier: Rekord i C20 og fire eliteaktier efte..
Relateret debat
01 mar - 
Mener du stadigvæk, at din analyse er korrekt? Ov..
28 feb - 
Se den tekniske analyse her.

Valby, 2017-01-25 08:00 CET (GLOBE NEWSWIRE) --

H. Lundbeck A/S (Lundbeck) is collaborating with IBM’s Watson Health to accelerate the development of innovative medicines to treat psychiatric and neurological disorders. The collaboration will combine Lundbeck’s expertise in the treatment of psychiatric and neurological disorders with IBM’s cognitive and knowledge-based analytics to foster the discovery and development of new innovative treatments of disorders such as schizophrenia and Parkinson’s disease.

“We strive to develop treatments that affect the underlying biological mechanisms of psychiatric and neurological disorders rather than treating only symptoms. By combining our expertise in brain research with IBM’s cognitive computer technology, we expect to improve our foundation for this work, so we can develop new and improved treatments for the 425 million people who suffer from the psychiatric and neurological disorders which Lundbeck focuses on,” says Anders Gersel Pedersen, Executive Vice President, Research & Development at Lundbeck.

Better understanding of diseases

This collaboration will help Lundbeck establish an innovative approach and new platform for real world evidence and advanced analytics where Lundbeck can take advantage of Watson technology across clinical data from millions of anonymized patient lives made available through the Watson Health Cloud.

In addition, this platform will allow Lundbeck to use the Watson technologies across additional Lundbeck data (clinical or other) as well as claims data that will be provided through this collaboration and made available in the Watson Health Cloud. Finally, Lundbeck will leverage IBM Watson for drug discovery to take advantage of a knowledge-driven approach and in support of the identification of potential new drug targets and alternative drug indications to accelerate discovery and advance the development of therapies.

“IBM can help create data-driven hypotheses based on Lundbeck’s questions, which can then be used in further research on fighting psychiatric and neurological disorders. Firstly, we will launch projects within schizophrenia and Parkinson’s disease, which we hope will help us better understand these diseases and possible treatments,” says Anders Gersel Pedersen.

Contacts

Mads Kronborg                                                                                    

Senior Director, Corporate Communication                                                 

Mobile: +45 30 83 28 51                                    

E-mail: mavk@lundbeck.com                                                    

 

About Lundbeck

H. Lundbeck A/S (LUN.CO, LUN DC, HLUYY) is a global pharmaceutical company specialized in psychiatric and neurological disorders. For more than 70 years, we have been at the forefront of research within neuroscience. Our key areas of focus are depression, schizophrenia, Parkinson's disease and Alzheimer's disease.

An estimated 700 million people worldwide are living with psychiatric and neurological disorders and far too many suffer due to inadequate treatment, discrimination, a reduced number of working days, early retirement and other unnecessary consequences. Every day, we strive for improved treatment and a better life for people living with psychiatric and neurological disorders – we call this Progress in Mind. Read more at www.lundbeck.com/global/about-us/progress-in-mind.

Our approximately 5,000 employees in 55 countries are engaged in the entire value chain throughout research, development, manufacturing, marketing and sales. Our pipeline consists of several late-stage development programmes and our products are available in more than 100 countries. We have research centres in China and Denmark and production facilities in China, Denmark, France and Italy. Lundbeck generated revenue of DKK 14.6 billion in 2015 (EUR 2 billion; USD 2.2 billion).

For additional information, we encourage you to visit our corporate site www.lundbeck.com and connect with us on Twitter at @Lundbeck.

Opret kommentar

Relateret debat

  • 1 uge
  • 1 måned
  • 1 År
Ingen indlæg

Nets-aktien har sat kurs mod største stigning i år

26-04-2017 15:50:39
Nets-aktien er onsdag sprunget i plus for året og ligger til at lukke med den største kursstigning siden nytår. Fremgangen falder sammen med en dugfrisk analyse fra den amerikanske storbank Citi, der ifølge Bloomberg News nævner muligheden for, at Nets kan være en interessant opkøbsmulighed for franske Worldline.Aktien i Nets ligger ved 15.40-tiden 3,3 pct. højere i 125,10 kr. Siden nytår er Nets ..

Shipping: Baltic Dry-indekset falder 0,6 pct. til 1147 point

26-04-2017 14:05:11
Tørlastindekset Baltic Dry falder onsdag for syvende børsdag på stribe - denne gang med 0,6 pct. til 1147 point. Det fremgår af data fra Bloomberg News.Baltic Dry-indekset udarbejdes af London-baserede Baltic Exchange og dækker priserne for at få fragtet last som kul, korn og jernmalm. Indekset er baseret på en daglig rundspørge til mæglere over hele verden.Baltic Dry ramte et foreløbigt højdepunk..

Express Scripts lider efter afsked med megakunde - citat

26-04-2017 09:10:44
Express Scripts, der er USA's største indkøber af medicin, er havnet i en krise, efter at selskabet mistede sin største kunde, sundhedsforsikringsselskabet Anthem. Forsikringsselskabet har hidtil bidraget med 17,1 mia. dollar til Express Scripts toplinje (på cirka 100 mia. dollar i 2016, red.).Det skriver the Wall Street Journal.I flere år har Express Scripts været stolte over, at have en simpel f..

Mest læste nyheder

  • 24 timer
  • 48 timer
  • 1 uge
1
Aktier/Danske: Tre vigtige døgn venter aktiemarkederne
2
Trumps skattereform koster dyrt - citat
3
Aktier/tendens: Positive takter i regnskabsstorm og venten på Trump
4
Aktier/åbning: Novozymes spurter frem og trækker eliteindeks med sig
5
Novozymes leverer højere vækst end ventet fra årets start

Relaterede aktiekurser

Lundbeck A/S 353,30 0,0% Aktiekurs uændret
H.Lundbeck A/S DKK5 51,42 0,0% Aktiekurs uændret

Køb- og salgsanbefalinger

  • Trend
  • Pengemaskinen

Copyright Euroinvestor A/S 2017  Disclaimer Privatlivspolitik
Aktieinformation leveres af Interactive Data.
Data er forsinket 15-20 minutter iht. de enkelte børsers regler om videredistribution.
 
27. april 2017 07:19:32
(UTC+01:00) Brussels, Copenhagen, Madrid, Paris
Version: LiveBranchBuild_20170403.1 - EUROWEB2 - 2017-04-27 07:19:32 - 2017-04-27 07:19:32 - 1 - Website: OKAY

Når du besøger Euroinvestor.dk accepterer du, at der anvendes cookies, som vi og vores samarbejdspartnere benytter til funktionalitet, statistik og markedsføring. Læs mere om cookies på Euroinvestor.dk her

x